Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Study to Evaluate the Efficacy and Safety of Fruquitinib in Combination With Paclitaxel Versus Paclitaxel Alone in Second Line Gastric Cancer

Trial Profile

A Phase III Study to Evaluate the Efficacy and Safety of Fruquitinib in Combination With Paclitaxel Versus Paclitaxel Alone in Second Line Gastric Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Sep 2018

At a glance

  • Drugs Fruquintinib (Primary) ; Paclitaxel (Primary)
  • Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
  • Focus Proof of concept; Registrational; Therapeutic Use
  • Acronyms FRUTIGA
  • Sponsors Hutchison MediPharma
  • Most Recent Events

    • 05 Sep 2018 According to a Chi-Med media release, an interim analysis to establish proof-of-concept (POC) is anticipated during the first half of 2019, and if successful could trigger a POC milestone from Lilly.
    • 31 Aug 2018 Biomarkers information updated
    • 27 Jul 2018 According to a Chi-Med media release, an interim analysis from this study is intended in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top